Nonmetastatic thoracic neuroblastomas: a review of 40 cases

Med Pediatr Oncol. 1991;19(4):253-7. doi: 10.1002/mpo.2950190408.

Abstract

From 1982 to 1987, 40 children with non-metastatic thoracic neuroblastoma were treated with the same therapeutic regimen. According to TNM staging, there were 11 CS I, 19 CS II, and 10 CS III. All patients underwent surgery; 30 had primary surgical excision; in 10 whose tumors were deemed unresectable, surgery was delayed until after a trial of chemotherapy. Operation was completed by several courses of chemotherapy in case of microscopic residual disease or regional lymph node involvement; radiotherapy was delivered in case of gross residual disease. Using this therapeutic approach, EFS is 92% with a median follow-up of 40 months. Severe complications were rare and sequellae appear to be related to the disease, i.e., neurologic consequences of cord compression.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neoplasm Staging
  • Neuroblastoma / mortality
  • Neuroblastoma / pathology
  • Neuroblastoma / secondary
  • Neuroblastoma / therapy*
  • Radiotherapy Dosage
  • Survival Rate
  • Thoracic Neoplasms / mortality
  • Thoracic Neoplasms / pathology
  • Thoracic Neoplasms / therapy*
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Doxorubicin
  • Cyclophosphamide